VNOV (VitaNova Life Sciences) PE Ratio without NRI: At Loss (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNOV VitaNova Life Sciences Corp VNOV
51 GF Score
Price $1.38
GF Value $5.95
! 1 Warning Sign
View Full Analysis

What is VitaNova Life Sciences PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-08-01), VitaNova Life Sciences's share price is $1.38. VitaNova Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01. Therefore, VitaNova Life Sciences's PE Ratio without NRI for today is At Loss.

During the past 10 years, VitaNova Life Sciences's highest PE Ratio without NRI was 225.00. The lowest was 0.00. And the median was 27.00.

VitaNova Life Sciences's EPS without NRI for the three months ended in Apr. 2026 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.

As of today (2026-08-01), VitaNova Life Sciences's share price is $1.38. VitaNova Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01. Therefore, VitaNova Life Sciences's PE Ratio (TTM) for today is At Loss.

During the past years, VitaNova Life Sciences's highest PE Ratio (TTM) was 225.00. The lowest was 0.00. And the median was 27.00.

VitaNova Life Sciences's EPS (Diluted) for the three months ended in Apr. 2026 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.01.

VitaNova Life Sciences's EPS (Basic) for the three months ended in Apr. 2026 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.00.


VitaNova Life Sciences  (OTCPK:VNOV) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


VitaNova Life Sciences PE Ratio without NRI Related Terms


VitaNova Life Sciences PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for VitaNova Life Sciences's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VitaNova Life Sciences PE Ratio without NRI Chart

VitaNova Life Sciences Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss 60.00 5.40 At Loss

VitaNova Life Sciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.40 5.40 48.30 60.38 At Loss

VNOV vs HKPD, COSM, SNYR: PE Ratio without NRI Comparison

For the Medical Distribution subindustry, VitaNova Life Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VitaNova Life Sciences PE Ratio without NRI vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where VitaNova Life Sciences's PE Ratio without NRI falls into.


VNOV
51GF Score
VitaNova Life Sciences Corp VNOV
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VitaNova Life Sciences PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

VitaNova Life Sciences's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=1.38/-0.008
=-172.5(At Loss)

VitaNova Life Sciences's Share Price of today is $1.38.
VitaNova Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is VitaNova Life Sciences (VNOV) Overvalued in 2026?

Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued. The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.

Key valuation signals for VNOV:

  • PE Ratio without NRI: At Loss
  • GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VitaNova Life Sciences Business Description

Address 30 E Broadway, Suite 603, New York, NY, USA, 10002
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score

Get the complete analysis for VNOV

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$5.95
GF Value